Category: Case Studies – IN

Patient: 40 years – Female diagnosed with Renal cell carcinoma Clinical Testing: Treatment Options: The MSH6 gene mutation is indicative

Patient: 66 years – Male diagnosed with High grade urothelial papillary carcinoma Clinical Testing: Treatment Options: In general CDKN2A deficient

Patient: 68 years – Female diagnosed with Intrahepatic Cholangiocarcinoma Clinical Testing: Treatment Options: MEK Inhibitor (Binimetinib) treatment can be used

Patient: 69 years – Male diagnosed with Adenocarcinoma-Gallbladder Clinical Testing: Treatment Options: As per the NCCN recommendations ERBB2 mutations benefit

Patient: 54 years – Male diagnosed with Squamous cell carcinoma of Buccal Mucosa Clinical Testing: Treatment Options: Overall preclinical and

Patient: 52 years – Male diagnosed with Adenocarcinoma Lung with Brain metastasis Clinical Testing: Treatment Options: Osimertinib is standard of

Patient: 54 years – Female diagnosed with Recurrent Metastatic Ovarian Adenocarcinoma Clinical Testing: Treatment Options: Co-occurring mutations in BRAF and

Patient: 67 years – Male diagnosed with Well-Differentiated Adenocarcinoma of Stomach Clinical Testing: Treatment Options: Various pre-clinical and clinical trials

Patient: 48 years – Female diagnosed with left breast cancer Clinical Testing: Treatment Options: The presence of HER2 amplification suggests

Patient: 52 years – Female diagnosed with Signet Ring Cell Adenocarcinoma of Colon Clinical Testing: Treatment Options: The presence of